Page 113

_ 113 Item Details($) Appropriations($) ITEM 101. First Year Second Year First Year Second Year FY2025 FY2026 FY2025 FY2026 V., Item 113, Chapter 1, 2024 Special Session I, shall be made available to the Department of General Services to demolish derelict structures, perform remediation, and market for sale the Central Virginia Training Center property in Madison Heights, Virginia. Proceeds from the sale of the property shall be deposited in the Behavioral Health and Developmental Services Trust Fund. Any funding remaining at the end of fiscal year 2025 shall be carried forward to the next fiscal year and reappropriated for the purposes described in this paragraph. U. Out of this appropriation, $7,500,000 the first year from the general fund is provided to the University of Virginia Medical Center for the improvement of a facility to create advanced laboratory space to support the scale up of fast-growing life sciences companies. Prior to the release of any funding in this paragraph, the University of Virginia Medical Center shall enter into a Memorandum of Understanding (MOU) with the Virginia Economic Development Partnership Authority, demonstrate a match of non- state funds equal to the amount provided in this paragraph, and the Department of Housing and Community Development shall verify to the Virginia Economic Development Partnership Authority that the Virginia Growth and Opportunity Fund grantee subject to GO Virginia Statewide Competitive Grant Contract Number 25-GOVA-10 has successfully completed the milestones required of the contract through the fourth quarter of 2025. The MOU shall include: (i) the names of the prospective occupants of the renovated lab space; and (ii) provisions related to annual reporting by the University of Virginia Medical Center on activities occurring in the renovated lab for a duration of no longer than five years including a sustainability plan for the long-term operations of the laboratory space. Any funding remaining at the end of the fiscal year 2025 shall be carried forward into the next fiscal year and reappropriated for the purposes described in this paragraph U. V. Out of the amounts in this item, $1,000,000 the first year from the general fund shall be provided to Chesterfield County to support site design and engineering activities for a major energy related economic development project. Such funding shall be contingent upon the execution of a Memorandum of Understanding between the Virginia Economic Development Partnership Authority and Chesterfield County that requires an equal local match and structures this funding on a reimbursement basis. The amounts provided in this paragraph V. shall not revert to the general fund at the end of any fiscal year, but shall be carried forward and reappropriated. W. Out of this appropriation, $3,000,000 the first year from the general fund is provided to the Virginia Economic Development Partnership Authority to support a non-profit operating a pharmaceutical manufacturing facility in developing a fast-acting insulin. Prior to any funds being disbursed, the authority shall enter into a Memorandum of Understanding (MOU) with a non-profit organization and the company shall demonstrate a match of non-state funds equal to the amount provided in this paragraph. The MOU shall include: (i) a commitment by the company to produce a fast-acting biosimilar insulin at a price of not more than $30 per vial and not more than $55 for five pre-filled insulin pens; (ii) provisions related to the repayment of the funds provided in this paragraph should the company fail to produce and distribute a low-cost insulin; and (iii) annual reporting by the company to the authority on the development of the fast-acting biosimilar insulin. At the conclusion of the project, the company shall be required to report to the authority on the: (i) jobs created as a result of the investment; (ii) estimated savings to residents of the Commonwealth from purchase of low-cost insulin; and, (iii) estimated potential savings to the Commonwealth as a self-insured employer from the availability of affordable insulin manufactured at a non-profit facility in Virginia. Any funding remaining at the end of the fiscal year 2025 shall be carried forward into the next fiscal year and reappropriated for the purposes described in this paragraph W. X. Out of this appropriation, $4,000,000 the first year from the general fund is provided to the City of Roanoke for the improvement of an existing facility to create advanced laboratory space for new cell/gene therapy companies across southwestern Virginia. Prior to the release of any funding in this paragraph, the City of Roanoke shall enter into a Memorandum of Understanding (MOU) with the Virginia Economic Development Partnership Authority, demonstrate a match of non-state funds equal to the amount provided in this paragraph from either cash or in-kind contributions, and confirm the commitment of an anchor tenant that specializes in new cell/gene therapy research and is